Foghorn therapeutics announces new preclinical data for fhd-286 in aml to be presented at the american society of hematology annual meeting

Cambridge, mass., dec. 05, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical data for its fhd-286 program will be presented in a poster at the 64th annual american society of hematology (ash) meeting. the meeting will be held december 10–12, 2022 in new orleans, la.
FHTX Ratings Summary
FHTX Quant Ranking